Impact of Metabolic Syndrome on Psoriasis Treatment
Author Information
Author(s): Mustață Maria-Lorena, Ionescu Mihaela, Radu Lucrețiu, Neagoe Carmen-Daniela, Ahrițculesei Roxana-Viorela, Cîmpeanu Radu-Cristian, Matei Daniela, Amzolini Anca-Maria, Predoi Maria-Cristina, Ianoși Simona-Laura, Zhang Duo
Primary Institution: University of Medicine and Pharmacy of Craiova, Romania
Hypothesis
How does metabolic syndrome affect the treatment response in psoriasis patients?
Conclusion
Managing metabolic syndrome is crucial for improving psoriasis treatment outcomes.
Supporting Evidence
- Patients with psoriasis and metabolic syndrome showed less improvement in PASI scores compared to those with psoriasis alone.
- Anti-IL-17 treatments provided the best long-term results.
- Obesity and metabolic dysfunction negatively impacted treatment efficacy.
- Statistically significant differences were found in treatment responses based on the presence of metabolic syndrome.
- Leptin levels correlated with PASI scores, indicating a link between metabolic health and psoriasis severity.
Takeaway
This study shows that people with psoriasis and metabolic syndrome may not respond as well to treatments as those with just psoriasis.
Methodology
150 patients were treated with various biologic therapies and their PASI scores were measured over one year.
Potential Biases
The predominance of male patients in the PSO-MS subgroup may introduce bias in the findings.
Limitations
The study had a small sample size and focused on a specific demographic, which may limit the generalizability of the results.
Participant Demographics
38.67% women and 61.33% men, ages ranged from 26 to 76 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website